Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — H1 2026 Earnings Presentation
14 slides from Bioporto A/s's earnings presentation, Aug 20, 2026
Slide 1: BioPorto Half Year Financials 2026
BioPorto Half Year Financials 2026 August 20, 2026 Carsten Buhl, CEO, & Klaus Juhl Wulff, CFO 1
Slide 2: Forward-looking Statements
Forward-looking Statements References herein to this presentation shall mean and include this forward-looking statements to reflect subsequent events or document, any oral presentation accompanying this document provided circumstances after the date of this presentation. by BioPorto A/S (the “Compan
Slide 3: BioPorto; invest in Acute Kidney Injury (AKI)
BioPorto; invest in Acute Kidney Injury (AKI) Clear inflection points for an early-stage in vitro diagnostics (IVD) company Clinical proven AKI solution … … a focused company … … clear future inflection points © Copyright BioPorto | 3
Slide 4: The "Forward" Strategic Plan
The ”Forward” Strategic Plan Focus on execution of Market Access & Commercialization to transform kidney care ASPIRATIONS + 60 U.S. Hospitals 2H 2028 Cash 1 Adoption + Validation Study 2026 Flow Positive + 100 Global Hospitals FY 2028 Revenue 2 High Growth + Adult Indication 2027 135-185m DKK + 170
Slide 5: The unmet AKI need
The unmet AKI need The clinician's, patient and society perspective Need for earlier detection AKI is common, 1 in 5 hospitalized patients develop AKI, up to 2 in 3 ICU patients* and kidney injury often develops silently, with few or no symptoms during the early stages missed early, and costly Need
Slide 6: The clinical challenge considering AKI
The clinical challenge considering AKI Kidney injury is common (20%*), often silent, and currently typically detected too late Adequate Filtration & Undamaged or Reduced Current standard of care focus on the Filtration & Injured functional filtration Standard of Care The NGAL Test/ProNephro AKI Seru
Slide 7: BioPorto's technology & regulatory status
BioPorto’s technology & regulatory status Pediatric FDA-cleared kidney injury biomarker positioned for broader market expansion Technology Adult Clinical Validation Study designed to identifying adult patients at risk of developing moderate-to-severe AKI at ICU Regulatory Pediatric FDA Adult Clearan
Slide 8: Business Update anno August 2026
Business Update anno August 2026 Consistent progress in the 9 months from initiation of the Forward Strategy Market Access Commercialization 1 Adult Cut-off Study Completion Jan26 41% US RUO growth y-o-y 1H26 2 Pre-Sub & Meeting with FDA Mar/Jun26 +10 new US RUO hospitals in 1H26 3 Adult Validation
Slide 9: +60 Hospitals by end of 2026 – Creating Adoption
+60 Hospitals by end of 2026 – Creating Adoption Expected Development of # of US Hospitals from 2024-2026 +36% 60 • Creating awareness and 54 understanding; to create the +22% future demand 44 • NGAL Research Use Only 36 (RUO) & continued focus on the Pediatric segment • Focus on the market in North
Slide 10: NGAL Sales US continuing strong growth
NGAL Sales US continuing strong growth US NGAL RUO sales (accumulated 12 months rolling at constant exchange rates) 25 +51% 22,8 Q2 2025 → Q2 2026 20 19,3 17,8 16,1 15,1 DKKm 15 14,2 13,7 13,0 12,3 11,8 10,1 10,2 10 8,7 5 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 202
Slide 11: Key financials for H1 2026
Key financials for H1 2026 In Q2 the Company performed a voluntary product recall concerning a lot sold in H2 2025. This impacted revenue one-time negatively by DKK 2.8 million and adjusted EBITDA negatively by DKK 3.0 million. Total NGAL operative* revenue of DKK 15.2 million, an increase of 34% co
Slide 12: 2026 Financial Guidance
2026 Financial Guidance Unchanged following the AntiBody divestment in April Total revenue in Total NGAL Adjusted EBITDA 2026 revenue in 2026 loss in 2026 DKK 38-48 DKK 33-42 DKK 58-68 million (48-58)* million (33-42)* million (50-60)* Expected NGAL revenue growth of 20-50% in 2026 Lower expected ad
Slide 13: Why BioPorto as the investment
Why BioPorto as the investment An opportunity at the changing intersection of diagnostics & kidney care Large Unmet Need Proven Technology Regulatory & KOL Foundation $700m $3bn- Competitive Position Market Opportunity Scalable Growth 13 © Copyright BioPorto |
Slide 14: Questions & Answers
Questions & Answers IR Contact Klaus Juhl Wulff, CFO – kjw@bioporto.com +45 2563 3990 | bioporto.com © Copyright BioPorto |